BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29607978)

  • 61. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids.
    Tamechika SY; Ohmura SI; Maeda S; Naniwa T
    J Bone Miner Metab; 2023 Mar; 41(2):203-211. PubMed ID: 36512086
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting.
    Chiha M; Myers LE; Ball CA; Sinacore JM; Camacho PM
    Endocr Pract; 2013; 19(6):989-94. PubMed ID: 24013976
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Calcif Tissue Int; 2017 Oct; 101(4):396-403. PubMed ID: 28589205
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study.
    Yoshida T; Kinoshita H; Taniguchi H; Yanishi M; Sugi M; Matsuda T
    Osteoporos Int; 2020 Jul; 31(7):1251-1259. PubMed ID: 31993719
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis.
    Igase M; Kohara K; Tabara Y; Ohara M; Takita R; Ochi M; Okada Y; Miki T
    Menopause; 2014 Sep; 21(9):962-6. PubMed ID: 24552979
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
    Nasomyont N; Hornung LN; Gordon CM; Wasserman H
    Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients.
    Iba K; Takada J; Sonoda T; Yamashita T
    J Bone Miner Metab; 2020 Mar; 38(2):240-247. PubMed ID: 31667583
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients.
    Mukaiyama K; Uchiyama S; Nakamura Y; Ikegami S; Taguchi A; Kamimura M; Kato H
    Tohoku J Exp Med; 2015 Dec; 237(4):339-43. PubMed ID: 26639092
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical characteristics and bisphosphonates treatment of rare pregnancy- and lactation-associated osteoporosis.
    Li LJ; Zhang J; Gao P; Lv F; Song YW; Chang XY; Zhao DC; Wang O; Jiang Y; Xing XP; Xia WB; Li M
    Clin Rheumatol; 2018 Nov; 37(11):3141-3150. PubMed ID: 29946989
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study.
    Kaji H; Kuroki Y; Murakawa Y; Funakawa I; Funasaka Y; Kanda F; Sugimoto T
    Osteoporos Int; 2010 Sep; 21(9):1565-71. PubMed ID: 19921083
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bone mineral density in osteoporotic patients with pyogenic vertebral osteomyelitis: effect of early versus late treatment for osteoporosis.
    Kim J; Kim SW; Lee SY; Kim TH; Jung JH
    Osteoporos Int; 2018 Dec; 29(12):2761-2770. PubMed ID: 30225674
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
    Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
    J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis.
    Nakamura Y; Suzuki T; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Tohoku J Exp Med; 2017 Apr; 241(4):319-326. PubMed ID: 28458336
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of minodronate on the speed of sound of the calcaneus in postmenopausal women with an increased risk of fractures: A clinical practice-based observational study.
    Iwamoto J; Takada T
    J Chin Med Assoc; 2015 Oct; 78(10):591-6. PubMed ID: 26231577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.